G1 Therapeutics
Patents, Design & Utilities
Last updated:
List of all G1 Therapeutics patents 50 in total
| Status | Patent |
|---|---|
Grant | Utility: Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors Filling date: 26 Sep 2025 Issue date: 20 Sep 2022 |
Application | Utility: TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING Filling date: 26 Sep 2025 Issue date: 4 Aug 2022 |
Grant | Utility: Treatment of EGFR-driven cancer with fewer side effects Filling date: 26 Sep 2025 Issue date: 26 Jul 2022 |
Grant | Utility: Combination therapy for treatment of cancer Filling date: 26 Sep 2025 Issue date: 21 Jun 2022 |
Grant | Utility: G1T38 superior dosage regimes Filling date: 26 Sep 2025 Issue date: 14 Jun 2022 |
Application | Utility: PATIENT SELECTION FOR ENHANCEMENT OF ANTI-TUMOR IMMUNITY IN CANCER PATIENTS Filling date: 26 Sep 2025 Issue date: 9 Jun 2022 |
Application | Utility: TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS Filling date: 26 Sep 2025 Issue date: 9 Jun 2022 |
Grant | Utility: Morphic forms of G1T38 and methods of manufacture thereof Filling date: 26 Sep 2025 Issue date: 1 Mar 2022 |
Application | Utility: CDK INHIBITORS Filling date: 26 Sep 2025 Issue date: 23 Dec 2021 |
Application | Utility: MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF Filling date: 26 Sep 2025 Issue date: 16 Dec 2021 |
Application | Utility: TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY Filling date: 26 Sep 2025 Issue date: 30 Sep 2021 |
Application | Utility: THERAPEUTIC REGIMENS FOR TREATMENT OF CANCER USING ERIBULIN AND SELECTIVE CDK4/6 INHIBITOR COMBINATIONS Filling date: 26 Sep 2025 Issue date: 2 Sep 2021 |
Grant | Utility: Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors Filling date: 26 Sep 2025 Issue date: 17 Aug 2021 |
Application | Utility: HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION Filling date: 26 Sep 2025 Issue date: 15 Jul 2021 |
Grant | Utility: Transient protection of normal cells during chemotherapy Filling date: 26 Sep 2025 Issue date: 22 Jun 2021 |
Application | Utility: SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE Filling date: 26 Sep 2025 Issue date: 17 Jun 2021 |
Application | Utility: BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS Filling date: 26 Sep 2025 Issue date: 10 Jun 2021 |
Application | Utility: SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES Filling date: 26 Sep 2025 Issue date: 29 Apr 2021 |
Grant | Utility: Morphic forms of trilaciclib and methods of manufacture thereof Filling date: 26 Sep 2025 Issue date: 27 Apr 2021 |
Grant | Utility: Benzothiophene estrogen receptor modulators Filling date: 26 Sep 2025 Issue date: 20 Apr 2021 |
Grant | Utility: Transient protection of normal cells during chemotherapy Filling date: 26 Sep 2025 Issue date: 6 Apr 2021 |
Application | Utility: TRANSIENT PROTECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AGAINST IONIZING RADIATION Filling date: 26 Sep 2025 Issue date: 18 Mar 2021 |
Grant | Utility: CDK inhibitors Filling date: 26 Sep 2025 Issue date: 23 Feb 2021 |
Grant | Utility: HSPC-sparing treatments for RB-positive abnormal cellular proliferation Filling date: 26 Sep 2025 Issue date: 23 Feb 2021 |
Application | Utility: PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS Filling date: 26 Sep 2025 Issue date: 18 Feb 2021 |
Application | Utility: TREATMENT OF CANCERS HAVING DRIVING ONCOGENIC MUTATIONS Filling date: 26 Sep 2025 Issue date: 4 Feb 2021 |
Application | Utility: G1T38 SUPERIOR DOSAGE REGIMES Filling date: 26 Sep 2025 Issue date: 31 Dec 2020 |
Grant | Utility: Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines Filling date: 26 Sep 2025 Issue date: 15 Dec 2020 |
Grant | Utility: Substituted dihydropyrazino[1 ',2':1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents Filling date: 26 Sep 2025 Issue date: 10 Nov 2020 |
Application | Utility: HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS Filling date: 26 Sep 2025 Issue date: 5 Nov 2020 |
Application | Utility: TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY Filling date: 26 Sep 2025 Issue date: 5 Nov 2020 |
Application | Utility: HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION Filling date: 26 Sep 2025 Issue date: 22 Oct 2020 |
Application | Utility: ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS Filling date: 26 Sep 2025 Issue date: 10 Sep 2020 |
Application | Utility: CDK INHIBITORS Filling date: 26 Sep 2025 Issue date: 3 Sep 2020 |
Application | Utility: PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER Filling date: 26 Sep 2025 Issue date: 30 Jul 2020 |
Grant | Utility: Highly active anti-neoplastic and anti-proliferative agents Filling date: 26 Sep 2025 Issue date: 14 Jul 2020 |
Application | Utility: BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS Filling date: 26 Sep 2025 Issue date: 9 Jul 2020 |
Grant | Utility: CDK inhibitors Filling date: 26 Sep 2025 Issue date: 30 Jun 2020 |
Grant | Utility: Transient protection of normal cells during chemotherapy Filling date: 26 Sep 2025 Issue date: 26 May 2020 |
Grant | Utility: Antiproliferative pyrimidine-based compounds Filling date: 26 Sep 2025 Issue date: 19 May 2020 |
Grant | Utility: Benzothiophene estrogen receptor modulators Filling date: 26 Sep 2025 Issue date: 28 Apr 2020 |
Grant | Utility: Pyrimidine-based compounds for the treatment of cancer Filling date: 26 Sep 2025 Issue date: 14 Apr 2020 |
Application | Utility: TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS Filling date: 26 Sep 2025 Issue date: 23 Jan 2020 |
Application | Utility: TREATMENT OF EGFR-DRIVEN CANCER WITH FEWER SIDE EFFECTS Filling date: 26 Sep 2025 Issue date: 12 Dec 2019 |
Grant | Utility: Lactam kinase inhibitors Filling date: 26 Sep 2025 Issue date: 5 Nov 2019 |
Application | Utility: COMBINATION THERAPY FOR TREATMENT OF CANCER Filling date: 26 Sep 2025 Issue date: 24 Oct 2019 |
Application | Utility: PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS Filling date: 26 Sep 2025 Issue date: 24 Oct 2019 |
Grant | Utility: HSPC-sparing treatments for Rb-positive abnormal cellular proliferation Filling date: 26 Sep 2025 Issue date: 8 Oct 2019 |
Grant | Utility: Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors Filling date: 26 Sep 2025 Issue date: 17 Sep 2019 |
Grant | Utility: Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferation Filling date: 26 Sep 2025 Issue date: 13 Aug 2019 |
Showing 1 to 50 of 50 patents.